Phacilitate

  • About Us
  • Insights and Resources
        • All Insights and Resources
          The latest and greatest Insights Phacilitate has to offer, across all our key sectors and mediums

        • Webinar Library
          View upcoming and past webinars about world of advanced therapies

           

          The Phacilitate Podcast
          Insightful conversations with industry leaders

        • Content Services
          We create game-changing content that empowers the advanced therapies industry

          • Industry Insights
            • Clinical Trials
            • Collaborations, Mergers and Acquisitions
            • Finance and Investment
            • GMP
            • Patient Access and Engagement
            • Regulatory and Standards
            • Reimbursement
            • Strategy
          • Manufacturing
            • Automation and Digitisation
            • Characterisation
            • CMC
            • GMP
            • Logistics
            • Partnering
            • Point of Care
            • Raw Materials
            • Scaling Up
            • Skills, Talent and Development
            • Supply Chain
          • Techniques
            • Allogeneic
            • Autologous
            • CAR-X
            • Cell Therapy
            • Gene Editing
            • Gene Therapy
            • NKx
            • Stem Cells
            • Viral/Non-viral Vectors
  • Events
  • Membership
    • Phacilitate Network
    • Women in Advanced Therapies
  • Latest News
  • Contact Us
Back
  • About Us
  • Insights and Resources
        • All Insights and Resources
          The latest and greatest Insights Phacilitate has to offer, across all our key sectors and mediums

        • Webinar Library
          View upcoming and past webinars about world of advanced therapies

           

          The Phacilitate Podcast
          Insightful conversations with industry leaders

        • Content Services
          We create game-changing content that empowers the advanced therapies industry

          • Industry Insights
            • Clinical Trials
            • Collaborations, Mergers and Acquisitions
            • Finance and Investment
            • GMP
            • Patient Access and Engagement
            • Regulatory and Standards
            • Reimbursement
            • Strategy
          • Manufacturing
            • Automation and Digitisation
            • Characterisation
            • CMC
            • GMP
            • Logistics
            • Partnering
            • Point of Care
            • Raw Materials
            • Scaling Up
            • Skills, Talent and Development
            • Supply Chain
          • Techniques
            • Allogeneic
            • Autologous
            • CAR-X
            • Cell Therapy
            • Gene Editing
            • Gene Therapy
            • NKx
            • Stem Cells
            • Viral/Non-viral Vectors
  • Events
  • Membership
    • Phacilitate Network
    • Women in Advanced Therapies
  • Latest News
  • Contact Us
Join Today
Sign In
Sign In
Join Today
  • All Insights and Resources
  • Industry Insights
  • Manufacturing
  • Techniques
Clinical Trials
Collaborations, Mergers and Acquisitions
Finance and Investment
GMP
Patient Access and Engagement
Regulatory and Standards
Reimbursement
Strategy
Automation and Digitisation
Characterisation
CMC
GMP
Logistics
Partnering
Point of Care
Raw Materials
Scaling Up
Skills, Talent and Development
Supply Chain
Allogeneic
Autologous
CAR-X
Cell Therapy
Gene Editing
Gene Therapy
NKx
Stem Cells
Viral/Non-viral Vectors
All News

CAR-X

Gilead’s Yescarta Demonstrates Improvement in Overall Survival for Aggressive Blood Cancers
23 March 2023
Gilead’s Yescarta Demonstrates Improvement in Overall Survival for Aggressive Blood Cancers
Kite’s Yescarta CAR-T cell therapy
GOSH Enters into Agreement with Leucid Bio at a New Therapy Manufacturing Center
16 March 2023
GOSH Enters into Agreement with Leucid Bio at a New Therapy Manufacturing Center
Leucid Bio, announced an agreement
Janssen Announces Achievement of Primary Endpoint in Phase-III CARVYKTI Study
7 February 2023
Janssen Announces Achievement of Primary Endpoint in Phase-III CARVYKTI Study
The Janssen Pharmaceutical Companies of
NICE Approves Kite’s Yescarta as NHS Treatment for Aggressive Forms of Blood Cancer
1 February 2023
NICE Approves Kite’s Yescarta as NHS Treatment for Aggressive Forms of Blood Cancer
NICE has announced the approval
POPULAR NEWS ITEMS
Image
23 March 2023

Gilead’s Yescarta Demonstrates Improvement in Overall Survival for Aggressive Blood Cancers

Image
14 March 2023

Pfizer Invests $43 Billion to Acquire Seagen

Image
2 March 2023

Early Adoption and Partnerships – The Secret to Commercialization Success?

Allogeneic Therapies: Can This be the Silver Bullet for All Future Cell Therapy Developers?
25 January 2023
Allogeneic Therapies: Can This be the Silver Bullet for All Future Cell Therapy Developers?
In this guest column, Renu
Aldevron Launches Eureca-V MAD7 at Advanced Therapies Week
20 January 2023
Aldevron Launches Eureca-V MAD7 at Advanced Therapies Week
Global leader in custom development
MicrofluidX Announces Partnership with CCRM for End-to-End Bioprocessing of CAR-T
19 January 2023
MicrofluidX Announces Partnership with CCRM for End-to-End Bioprocessing of CAR-T
UK-based provider of next-generation bioreactors
Top 10 Events in Cell & Gene Therapy 2022
18 January 2023
Top 10 Events in Cell & Gene Therapy 2022
It’s day 1 of Advanced
Load more News
RECOMENDED TOPICS
Allogeneic
Autologous
CAR-X
Cell Therapy
Cell-Based IO
Gene Editing
Gene Therapy
NKx
Stem Cells
Tissue Engineering
Viral/Non-Viral Vectors
POPULAR NEWS ITEMS
Image

Gilead’s Yescarta Demonstrates Improvement in Overall Survival for Aggressive Blood Cancers

Image

Pfizer Invests $43 Billion to Acquire Seagen

Image

Early Adoption and Partnerships – The Secret to Commercialization Success?

logo_footer
logo_mobile_footer
Company
  • About Us
  • Events
  • Contact Us
Resources
  • Insights and Resources
  • Latest News
  • Phacilitate Podcast
  • Content Services
Network
  • Sign In
  • Join Today
social_icon Linkedin
social_icon Twitter

Clarion Events Limited is registered in England and Wales, Company Number 00454826, VAT No. GB 843845601 Registered Office: Bedford House, 69-79 Fulham High Street, London, SW6 3JW, United Kingdom.

  • Privacy Policy
  • Code of Conduct
  • Terms & Conditions
  • Cookies
Phacilitate is a part of Clarion Events Limited. © Phacilitate 2022